Exhibit 99.1

Appendix 4C

Quarter Ended 31 March 2012

San Diego, California and Sydney, Australia (Monday 30 April 2012, AEST) – REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”) is pleased to provide its Appendix 4C Quarterly Report for the quarter ended 31 March 2012. The Appendix 4C, which has been prepared in U.S. dollars, is attached and the results disclosed in the Appendix 4C are unaudited.

As of 31 March 2012, the Company’s cash balance was US$54,574,000 and its interest-bearing investments were US$4,230,000 for a total of US$58,804,000. The current quarter end total reflects a decrease of US$5,583,000 from the 31 December 2011 balance of US$64,387,000, primarily as a result of expenditures related to normal operating activities. Included in the quarterly results were leasehold improvement expenditures for our San Diego facility and capital equipment totaling US$1,343,000. Also during the quarter ended 31 March 2012, we received US$309,000 from cash exercises of employee stock options.

The Company will file its Form 10-Q Quarterly Report (the “Quarterly Report”) with the U.S. Securities and Exchange Commission on or before 11 May 2012. The Quarterly Report provides financial statements, along with Management’s Discussion and Analysis of Financial Condition and Results of Operations, for the period ended 31 March 2012.

About REVA

REVA is a development stage medical device company incorporated in Delaware, USA, that is focused on the development and eventual commercialisation of its proprietary bioresorbable stent products. REVA’s lead product, the ReZolve^® scaffold, combines REVA’s proprietary stent design with a proprietary polymer that is metabolised and cleared from the body. The ReZolve scaffold is designed to offer full x-ray visibility, clinically relevant sizing, and a controlled and safe resorption rate. In addition, by early encapsulation in the artery tissue coupled with the loss of scaffold structure over time, the ReZolve scaffold may reduce the incidence of late forming blood clots, or thrombosis, a rare but serious problem associated with drug-eluting metal stents currently on the market. REVA will require clinical results and regulatory approval before it can begin selling the ReZolve scaffold.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management’s beliefs, assumptions, and expectations and on information currently available to management. All statements that are not historical, including those statements that address future operating performance and events or developments that we expect or anticipate will occur in the future, are forward-looking statements. You should not place undue reliance on

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 — +1 (858) 966-3000 — +1 (858) 966-3099 (FAX) — www.revamedical.com

AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 — +61 2 9231 3322 — +61 9229 2727 (FAX) — ARBN 146 505 777

REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability.

these forward-looking statements. Although management believes these forward-looking statements are reasonable as and when made, forward-looking statements are subject to a number of risks and uncertainties that may cause our actual results to vary materially from those expressed in the forward-looking statements, including our ability to obtain the regulatory approvals required to market our ReZolve scaffold, our ability to timely and successfully complete our clinical trials, our ability to protect our intellectual property position, our ability to commercialize our products if and when approved, our ability to develop and commercialize new products, and our estimates regarding our capital requirements and financial performance, including profitability. Other risks and uncertainties that may cause our actual results to vary materially from any forward-looking statements are described in the “Risk Factors” section in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (the “SEC”) on 29 February 2012. We may update our risk factors from time to time in our periodic reports or other current reports filed with the SEC. Any forward-looking statements in this announcement speak only as of the date when made. REVA does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

HEAD OFFICE: 5751 Copley Drive, San Diego, CA 92111 — +1 (858) 966-3000 — +1 (858) 966-3099 (FAX) — www.revamedical.com

AUSTRALIAN OFFICE: Level 6, 175 Macquarie Street, Sydney, NSW 2000 — +61 2 9231 3322 — +61 9229 2727 (FAX) — ARBN 146 505 777

REVA Medical, Inc., is a foreign company incorporated in Delaware, USA, whose stockholders have limited liability.

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Rule 4.7B

Appendix 4C

Quarterly report

for entities admitted

on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001, 24/10/2005.

Consolidated statement of cash flows

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

Non-cash financing and investing activities

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.

Acquisitions and disposals of business entities

Compliance statement

Print name: Katrina L. Thompson

Appendix 4C

Quarterly report for entities

admitted on the basis of commitments

Notes